Biblio Discovery — Demo Discovery Service

36 hasil

Menampilkan 1–20 · 0,18 detik · RSS

Jurnal

Journal of Thoracic Oncology

Scopus

ISSN 1556-0864 · Elsevier BV · 36 artikel di indeks

  1. Artikel Jurnal Teks lengkap

    Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study

    Nicolas M Girard; Jair Bar; Pilar Garrido dkk.

    Journal of Thoracic Oncology · 2022 · Inggris · OpenAlex Scopus

    INTRODUCTION: The phase 3 PACIFIC trial established consolidation therapy with durvalumab as standard of care for patients with unresectable, stage III NSCLC and no disease progression after definitive chemoradiotherapy (CRT). The observational PACIFIC-R study assesses the real-world effectiveness…

  2. Artikel Jurnal Teks lengkap

    Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial

    Corinne Faivre Finn; David Vicente; Takayasu Kurata dkk.

    Journal of Thoracic Oncology · 2021 · Inggris · OpenAlex Scopus

    INTRODUCTION: In the Phase 3, placebo-controlled PACIFIC trial of patients with unresectable, stage III NSCLC without disease progression after concurrent chemoradiotherapy, consolidative durvalumab was associated with significant improvements in the primary end points of overall survival (OS)…

  3. Artikel Jurnal Teks lengkap

    First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

    Luis G Paz-Ares; Suresh S. Ramalingam; Tudor–Eliade Ciuleanu dkk.

    Journal of Thoracic Oncology · 2021 · Inggris · OpenAlex Scopus

    INTRODUCTION: In CheckMate 227, nivolumab plus ipilimumab prolonged overall survival (OS) versus chemotherapy in patients with tumor programmed death-ligand 1 (PD-L1) greater than or equal to 1% (primary end point) or less than 1% (prespecified descriptive analysis). We report results with minimum…

  4. Artikel Jurnal

    The 2021 WHO Classification of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors?

    Alexander Marx; John K.C. Chan; Lara Chalabreysse dkk.

    Journal of Thoracic Oncology · 2021 · Inggris · OpenAlex Scopus

    This overview of the fifth edition of the WHO classification of thymic epithelial tumors (including thymomas, thymic carcinomas, and thymic neuroendocrine tumors [NETs]), mediastinal germ cell tumors, and mesenchymal neoplasms aims to (1) list established and new tumor entities and subtypes and (2)…

  5. Artikel Jurnal Teks lengkap

    Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial

    Shun Lü; Jie Wang; Yan Yu dkk.

    Journal of Thoracic Oncology · 2021 · Inggris · OpenAlex Scopus

    INTRODUCTION: Tislelizumab, an anti-programmed cell death protein-1 antibody, was specifically engineered to minimize FcɣR macrophage binding to abrogate antibody-dependent phagocytosis. Compared with chemotherapy alone, tislelizumab plus chemotherapy may improve clinical outcomes in patients with…

  6. Artikel Jurnal Teks lengkap

    Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis

    David Planchard; Benjamin Besse; Harry J.M. Groen dkk.

    Journal of Thoracic Oncology · 2021 · Inggris · OpenAlex Scopus

    INTRODUCTION: Dabrafenib plus trametinib was found to have robust antitumor activity in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC). We report updated survival analysis of a phase 2 study (NCT01336634) with a minimum of 5-year follow-up and updated genomic data. METHODS: Pretreated…

  7. Artikel Jurnal Teks lengkap

    Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial

    D. Ross Camidge; Hye Ryun Kim; Myung‐Ju Ahn dkk.

    Journal of Thoracic Oncology · 2021 · Inggris · OpenAlex Scopus

    INTRODUCTION: In the phase 3 study entitled ALK in Lung cancer Trial of brigAtinib in 1st Line (ALTA-1L), which is a study of brigatinib in ALK inhibitor-naive advanced ALK-positive NSCLC, brigatinib exhibited superior progression-free survival (PFS) versus crizotinib in the two planned interim…

  8. Artikel Jurnal Teks lengkap

    Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC

    Roy S. Herbst; Edward B. Garon; Dong‐Wan Kim dkk.

    Journal of Thoracic Oncology · 2021 · Inggris · OpenAlex Scopus

    INTRODUCTION: In the KEYNOTE-010 study, pembrolizumab improved overall survival (OS) versus docetaxel in patients with previously treated, advanced NSCLC with programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) ≥50% and ≥1%. We report 5-year efficacy and safety follow-up for the…

  9. Artikel Jurnal Teks lengkap

    Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study

    Fiona Helen Blackhall; Kevin Jao; Laurent Greillier dkk.

    Journal of Thoracic Oncology · 2021 · Inggris · OpenAlex Scopus

    Introduction DLL3, an atypical Notch ligand, is expressed in SCLC tumors but is not detectable in normal adult tissues. Rovalpituzumab tesirine (Rova-T) is an antibody-drug conjugate containing a DLL3-targeting antibody tethered to a cytotoxic agent pyrrolobenzodiazepine by means of a…

  10. Artikel Jurnal

    IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC

    Mark A. Socinski; Makoto Nishio; Robert M. Jotte dkk.

    Journal of Thoracic Oncology · 2021 · Inggris · OpenAlex Scopus

    INTRODUCTION: We report the final overall survival (OS) analyses of atezolizumab-carboplatin-paclitaxel (ACP [experimental arm]) and OS data with approximately 39.8 months of median follow-up with atezolizumab-bevacizumab-carboplatin-paclitaxel (ABCP) versus bevacizumab-carboplatin-paclitaxel (BCP)…

  11. Artikel Jurnal

    Biomarker Discovery and Validation: Statistical Considerations

    Fang‐Shu Ou; Stefan Michiels; Yu Shyr dkk.

    Journal of Thoracic Oncology · 2021 · Inggris · OpenAlex Scopus

    Biomarkers have various applications including disease detection, diagnosis, prognosis, prediction of response to intervention, and disease monitoring. In this era of precision medicine, having validated biomarkers to inform clinical decision making is more important than ever. In this article, we…